Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination
about
Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding SiteSang Froid in a time of trouble: is a vaccine against HIV possible?Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoproteinCo-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cellsProgress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles.Human immunodeficiency virus vaccine an update.Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and MacaquesBreadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigsAntibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virusMucosal vaccines against respiratory syncytial virusBoosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein.Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence.A versatile vector for the production of pseudotyped viruses expressing gp120 antigens from different clades of primary HIV-1 isolates.Serum neutralizing activities from a Beijing homosexual male cohort infected with different subtypes of HIV-1 in China.Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate.Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodiesTwo closely related Env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates.Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate.DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titersBiochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding sitePilot Study on the Use of DNA Priming Immunization to Enhance Y. pestis LcrV-Specific B Cell Responses Elicited by a Recombinant LcrV Protein Vaccine.Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formationStructural analysis of a novel rabbit monoclonal antibody R53 targeting an epitope in HIV-1 gp120 C4 region critical for receptor and co-receptor binding.DNA prime-protein boost using subtype consensus Env was effective in eliciting neutralizing antibody responses against subtype BC HIV-1 viruses circulating in China.Pilot study on the immunogenicity of paired Env immunogens from mother-to-child transmitted HIV-1 isolates.Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes.Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates.Heterologous prime-boost vaccination.Cross reactivity of serum antibody responses elicited by DNA vaccines expressing HA antigens from H1N1 subtype influenza vaccines in the past 30 years.DNA immunization.Improvement of antibody responses by HIV envelope DNA and protein co-immunization.Improved outlook on HIV-1 prevention and vaccine development.A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugsDNA Immunization for HIV Vaccine Development.Stabilization of a soluble, native-like trimeric form of an efficiently cleaved Indian HIV-1 clade C envelope glycoproteinHIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes.
P2860
Q27319450-1088C241-56F3-4372-9F94-EB25AD2BCC1AQ27487961-296AFC73-7027-4809-9164-6CC4C9BDA8E9Q28534454-5F491BFF-B3DF-4D87-9DC9-CF6964E150A9Q28732043-49847D80-6C04-4606-B15C-2942E3C20EAAQ30379200-CAF3BC12-5E38-4081-8B5F-76647A5E6A5EQ30418340-A558A821-8EBD-4353-87EA-28121602FFE7Q30432382-743B9A99-6D8E-4EBA-901E-9D5641461B61Q33683203-E44321EF-8885-44E9-8E4D-1E1747B95413Q33725679-9C029F6F-EBCC-41BB-818F-DB84D49E2378Q33759392-44135B79-FD88-471D-8FBC-E460DF9FCA65Q33769283-12C37648-0D52-4F61-86D1-F39963359902Q33837530-8A6E8CB1-B9AC-47C2-B2E0-75A51958116CQ33955745-AAA06156-CAD2-42E2-9778-7FD10CFFF7E1Q34016706-F9C00EA1-56D9-4DDC-94B9-4076D5C31324Q34444535-F9212618-D9BF-40CE-9EE8-F63925B05268Q34456367-EBCA9A03-F5F7-4272-8D1C-FD474BFDA156Q34551010-5B604B22-0C57-416F-A976-DBD03ED48717Q34982715-E8F851BB-5CB7-4C96-902A-1827D04204AFQ35076664-F9F55DC5-6898-48E5-8EE2-F4990D27C034Q35580892-1BC97696-EB62-4E78-B77D-4AE5E2136483Q35640984-CF909364-53F8-4C74-AC98-C858B257D80EQ35774051-76B6557F-794A-4251-BDEF-43C0B56A5AF5Q35826610-1552E27A-6DD9-4636-B7CE-86A511B173DEQ35893538-7E38416C-601D-4AB8-A5F5-67587EAEDBECQ35909563-B71ADF8E-3DFF-492B-B0E8-4E395AC29978Q36694841-01308B9D-00E2-4D28-A917-06A90FE175BFQ36694846-6313ABD7-E9F3-45C7-9FDC-DFADE2F034AEQ36827300-056E8ACA-C846-4925-906C-5A20CE459F5DQ36974754-87397E4F-F48B-42BE-9DE1-13663CA54D80Q37252966-A2821E5B-7074-42C3-B1DE-6E6F5571FC8FQ37336704-77E8331A-DEC8-43BA-BF47-B52670FDB580Q37509586-F16D2F01-55DB-4721-AAF6-AB59EA6FB03CQ37530450-D7C8E5A4-1F11-4EF0-AAEF-474221AE0CA9Q37576264-28B57AD6-8F2D-4636-A09C-6F1E2B01EC08Q37588371-8E92CA31-AD70-446C-8B28-310F2D85949FQ38009870-B1D44AD3-F470-4A85-B500-B83DA9310593Q38206520-58DFAA31-3189-417B-9EBF-68AB0F8E6D46Q38581981-42738156-6F8E-4526-B5E9-7BE578635D08Q38712684-1DFB5012-9387-4F4C-9FDE-69609366C57CQ39402539-80B9BEDD-1DD6-45C0-88C3-EF1FDDECCD27
P2860
Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Improved induction of antibodi ...... gp120 protein-only vaccination
@ast
Improved induction of antibodi ...... gp120 protein-only vaccination
@en
type
label
Improved induction of antibodi ...... gp120 protein-only vaccination
@ast
Improved induction of antibodi ...... gp120 protein-only vaccination
@en
prefLabel
Improved induction of antibodi ...... gp120 protein-only vaccination
@ast
Improved induction of antibodi ...... gp120 protein-only vaccination
@en
P2093
P2860
P356
P1433
P1476
Improved induction of antibodi ...... gp120 protein-only vaccination
@en
P2093
Emma T Crooks
James Binley
Michael Vaine
Pengfei Jiang
Shixia Wang
P2860
P304
P356
10.1128/JVI.00562-08
P407
P577
2008-05-21T00:00:00Z